Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, cash reserves at Prelude Therapeutics Inc fell by 5.31m. Cash Flow from Financing totalled 136.40m or -- of revenues. In addition the company used 107.06m for operations while cash used for investing totalled 34.65m.
Cash flow per share | -1.78 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 4.32 |
---|---|
Tangible book value per share | 4.32 |
More ▼
Balance sheet in USDView more
Current ratio | 7.83 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.0028 |
---|---|
Total debt/total capital | 0.0028 |
More ▼